Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) Short Interest Update

Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) was the target of a significant decrease in short interest during the month of March. As of March 15th, there was short interest totalling 21,100 shares, a decrease of 60.9% from the February 28th total of 53,900 shares. Based on an average daily volume of 28,500 shares, the days-to-cover ratio is presently 0.7 days. Currently, 0.0% of the shares of the stock are short sold.

Inhibitor Therapeutics Stock Performance

OTCMKTS:INTI traded down $0.00 on Friday, hitting $0.06. 2,000 shares of the stock were exchanged, compared to its average volume of 39,043. Inhibitor Therapeutics has a 52 week low of $0.04 and a 52 week high of $0.14. The stock has a market capitalization of $9.99 million, a price-to-earnings ratio of -5.80 and a beta of -0.55. The company’s 50-day moving average price is $0.06 and its 200 day moving average price is $0.07.

Inhibitor Therapeutics (OTCMKTS:INTI) last posted its quarterly earnings results on Friday, March 28th. The company reported ($0.01) earnings per share for the quarter.

Inhibitor Therapeutics Company Profile

Inhibitor Therapeutics, Inc, a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome.